Summary

Medication use patterns in systemic juvenile idiopathic arthritis (sJIA) are changing gradually and reflect significant treatment variability. Data from recent Phase 3 clinical trials of 2 biologic inhibiting agents, tocilizumab and canakinumab, may prompt further changes in treatment choices in the future, as these 2 agents show impressive response rates [Yokota S et al Lancet 2008; De Benedetti F et al. Arthritis Rheum 2010; De Benedetti F et al. Arthritis Rheum 2011; Brunner HI et al. ACR 2012 Abstract 759].